Samsung Biologics Sets PolyPeptide Bid
Samsung Biologics will launch its 1.46 billion franc takeover offer for PolyPeptide Group in September. The offer period runs from September 15 to October 12. PolyPeptide's board unanimously recommends shareholders accept.
Xurve View
Insights:
Xurve View
SAMSUNG BIOLOGICS CO LTD will launch a takeover offer worth $1.80 billion for POLYPEPTIDE GROUP AG in September, seeking to delist the Swiss target. The South Korean contract manufacturer aims to expand its footprint in peptide therapeutics through the acquisition. The transaction ranks among the largest cross-border deals in the pharmaceutical sector in Switzerland this year.
